Project CV-NCOV-001 – A Phase 1, partially blind, placebo-controlled, dose-esclation, first-in-human, clinical trial to…

Basic data

Acronym:
CV-NCOV-001
Title:
A Phase 1, partially blind, placebo-controlled, dose-esclation, first-in-human, clinical trial to evaluate the safety, reactogenicity and immunogenicity after 1 and 2 doses of the investigational SARS-COV-2 mRNA vaccine CVnCoV administered intramuscularly in healthy adults
Duration:
29/05/2020 to 29/05/2020
Abstract / short description:
Phase 1 trial to test the safety, tolerability and immunogenicity of a COVID-19 vaccine candidate
Keywords:
clinical trial
klinische Studie
COVID-19
SARS-COV-2
Impfstoff

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Faculty of Medicine
University of Tübingen

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Department VII, Tropical Medicine
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Help

will be deleted permanently. This cannot be undone.